Nuvalent NUVL
NUVL
$123.96 +0.00 (+0.00%)
At close: Jul 21, 2026 · 4:00 PM EDT

Nuvalent (NUVL) Total Non-Current Liabilities (2023 - 2026)

Nuvalent's (NUVL) quarterly Total Non-Current Liabilities came in at $156.8 million in Q1 2026, up 66.07% YoY from $94.4 million in Q1 2025, and down 4.59% on a QoQ basis from $164.3 million in Q4 2025.

Analysis

Nuvalent (NUVL) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends

Nuvalent (NUVL) has 3 years of Total Non-Current Liabilities data on file, last reported at $156.8 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 66.07% year-over-year to $156.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.8 million (up 66.07% YoY) and the FY2025 annual result came in at $164.3 million, up 128.36% from the prior year.
  • Total Non-Current Liabilities retreated to $156.8 million in Q1 2026, from $164.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $164.3 million in Q4 2025 to a low of $51.1 million in Q3 2024.
  • A 3-year average of $110.5 million and a median of $100.6 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2025 — Total Non-Current Liabilities surged 162.79% — and 2026, when it jumped 66.07%.
  • Tracing NUVL's Total Non-Current Liabilities over 3 years: stood at $72.0 million in 2024, then surged by 128.36% to $164.3 million in 2025, then retreated by 4.59% to $156.8 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $156.8 million (Q1 2026), $164.3 million (Q4 2025), and $134.4 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Nuvalent 9.75 Bn 9.75 Bn - 81.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 81.05 Mn
Dec 31, 2025 91.21 Mn
Sep 30, 2025 89.29 Mn
Jun 30, 2025 75.39 Mn
Mar 31, 2025 75.38 Mn
Dec 31, 2024 54.02 Mn
Sep 30, 2024 51.13 Mn
Dec 31, 2023 31.82 Mn